[
  {
    "uuid": "0f629328f383a809f1d42b9fe5c11c638475caf3",
    "url": "https://news.nestia.com/detail/Cosmogen%3A-A-100%25-paper-stick-and-a-full-PET-makeup-line/13311974",
    "ord_in_thread": 0,
    "parent_url": null,
    "author": "Premium Beauty News",
    "published": "2025-02-27T22:00:00Z",
    "title": "Cosmogen: A 100% paper stick and a full PET makeup line | Nestia",
    "text": "At Paris Packaging Week 2025 , Cosmogen remained true to its commitment to sustainability and performance , with innovative solutions combining mono-materials, advanced features and high-end aesthetics. Launched in 2023 to host anhydrous cosmetic formulas in a premium packaging solution minimizing the use of plastic, the Paper Stick now features a full-paper mechanism!",
    "highlightText": "",
    "highlightTitle": "",
    "highlightThreadTitle": "",
    "language": "english",
    "sentiment": "positive",
    "categories": [
      "Science and Technology"
    ],
    "topics": [
      "Science and Technology->biotechnology",
      "Science and Technology->scientific innovation",
      "Science and Technology->technology and engineering"
    ],
    "ai_allow": true,
    "has_canonical": false,
    "breaking": false,
    "webz_reporter": false,
    "external_links": [],
    "external_images": [],
    "entities": {
      "persons": [],
      "organizations": [],
      "locations": []
    },
    "syndication": {
      "syndicated": false,
      "syndicate_id": null,
      "first_syndicated": false
    },
    "trust": null,
    "rating": null,
    "crawled": "2025-02-28T00:09:34.433+02:00",
    "updated": "2025-02-28T00:09:34.433+02:00"
  },
  {
    "uuid": "5d7dc3fd1019c4b213cc8afb4e45ce29c5a11718",
    "url": "https://jam-news.net/bakhtiyar-hajiyev-case-arrests-in-azerbaijan",
    "ord_in_thread": 0,
    "parent_url": null,
    "author": "JAMnews | English",
    "published": "2024-09-26T23:58:00Z",
    "title": "Bakhtiyar Hajiyev case – arrests in Azerbaijan / JAMnews",
    "text": "Bakhtiyar Hajiyev case – arrests in Azerbaijan The trial of prominent human rights activist Bakhtiyar Hajiyev, arrested in December 2022, is ongoing in Baku, Azerbaijan . He has been in detention for nearly two years without a court verdict. Initially charged with hooliganism and contempt of court, he now faces five additional, more serious charges. At the latest hearing, Hajiyev announced that he no longer intends to participate in the process, calling the trial a “farce.” Abkhazia ratifies agreement with Russia on “mutual recognition of court decisions in economic matters” Reactions from Azerbaijan regarding Kamala Harris’s statement on the right of return for Karabakh Armenians Azerbaijan sees significant drop in disability pensioners: What’s behind the change? On September 25, at the latest hearing of Bakhtiyar Hajiyev’s case in the Baku Court on Grave Crimes, he submitted a written protest to prosecutor Eldar Hamza. According to Voice of America, the activist argued that the prosecutor had “violated the requirements of the Criminal Procedure Code by asking the witness questions about case materials that had not yet been reviewed in court.” Hajiyev also claimed that the prosecutor’s name appears on a sanctions list submitted to the U.S. Congress, indicating his involvement in politically motivated cases. Eldar Hamza responded by stating that no sanctions have been imposed on him. He added that his name was included in the U.S. Congress list because he served as the prosecutor in a trial involving Armenian separatists. The court did not grant Bakhtiyar Hajiyev’s motion. Bakhtiyar Hajiyev case – arrests in Azerbaijan Later, he filed another motion stating that he no longer wishes to participate in the upcoming court sessions. The activist explained this decision by citing the “artificial delays in the process,” the rejection of all his motions, and his belief that the court itself is “political and orchestrated.” “Therefore, there can be no talk of the court’s objectivity,” Hajiyev stated. The prosecutor opposed this motion, and the court denied it as well. Despite this, Hajiyev declared that he would not participate in the proceedings going forward. The process continued with the examination of the case documents. The date for the next court session has not been announced and has been postponed indefinitely. Bakhtiyar Hajiyev case – arrests in Azerbaijan Bakhtiyar Hajiyev was arrested in December 2022. Initially, he faced charges under Articles 221.2.2 (hooliganism by resisting a person performing duties to maintain public order) and 289.1 (contempt of court) of the Azerbaijan Criminal Code. Hajiyev was accused in connection with a complaint filed by journalist Ulviya Alovlu. A long-standing conflict exists between Hajiyev and Alovlu, with both accusing each other of defamation. During one of the court proceedings, a verbal altercation escalated into a physical confrontation. According to the charges, Hajiyev allegedly used violence against both Alovlu and court officer Orkhan Abdullayev during this incident. Forty-two-year-old Bakhtiyar Hajiyev earned his master’s degree from Harvard University in the United States. He is known for his criticism of the Azerbaijani authorities’ policies. Hajiyev has faced repeated arrests and repression. In 2011, he was detained on charges of evading military service and was recognized as a political prisoner. In August 2022, Hajiyev submitted a statement to the presidential administration renouncing his Azerbaijani citizenship due to violations of his rights.",
    "highlightText": "",
    "highlightTitle": "",
    "highlightThreadTitle": "",
    "language": "english",
    "sentiment": "negative",
    "categories": [
      "Politics",
      "Social Issue",
      "War, Conflict and Unrest"
    ],
    "ai_allow": true,
    "webz_reporter": false,
    "external_links": [],
    "external_images": [],
    "entities": {
      "persons": [
        {
          "name": "Bakhtiyar Hajiyev",
          "sentiment": "negative"
        },
        {
          "name": "Kamala Harris",
          "sentiment": "none"
        },
        {
          "name": "Eldar Hamza",
          "sentiment": "none"
        }
      ],
      "organizations": [
        {
          "name": "Voice of America",
          "sentiment": "none"
        }
      ],
      "locations": [
        {
          "name": "Abkhazia",
          "sentiment": "none"
        }
      ]
    },
    "syndication": {
      "syndicated": false,
      "syndicate_id": null,
      "first_syndicated": false
    },
    "rating": null,
    "crawled": "2024-09-27T03:13:30.933+03:00",
    "updated": "2024-09-27T03:13:30.933+03:00"
  },
  {
    "uuid": "049b8a503c40e1b50ea6827ac10fca3a8169757e",
    "url": "https://istoe.com.br/criacao-de-empregos-nos-eua-cai-a-12-000-em-outubro-taxa-de-desemprego-vai-a-41",
    "ord_in_thread": 0,
    "parent_url": null,
    "author": "admin3",
    "published": "2024-11-01T10:49:00Z",
    "title": "Cria\\u00e7\\u00e3o de empregos nos EUA cai a 12.000 em outubro, taxa de desemprego vai a 4,1%",
    "text": "01/11/2024 - 10:49 A criação de empregos nos Estados Unidos caiu drasticamente em outubro devido a furacões e greves que afetaram o país, segundo dados do Departamento de Trabalho divulgadas nesta sexta-feira, a quatro dias das eleições presidenciais. A maior economia do mundo criou 12.000 novos postos de trabalho no mês passado, abaixo das expectativas e dos 223.000 empregos de setembro, segundo o dado revisado. Mas em um sinal positivo, a taxa de desemprego se manteve sem mudanças em 4,1%. O número de novos contratos é muito inferior à prevista, já que os analistas esperavam 110.000, segundo o consenso do Market Watch. “É provável que as estimativas de empregos assalariados em determinados setores tenham sido alteradas pelos furacões”, explicou o governo em um comunicado à imprensa. Esses números se baseiam em duas pesquisas com famílias, empresas e órgãos governamentais após a passagem dos furacões Helene e Milton no final de setembro e início de outubro. “O emprego diminuiu no setor de manufatura devido a greves”, especialmente a de alguns trabalhadores da fabricante de aviões Boeing desde 13 de setembro. “O emprego continuou sua tendência de alta no setor de saúde e na administração pública”, informou o governo. Os números relativos à criação de empregos em agosto e setembro foram revisados para baixo, para 78.000 e 223.000, respectivamente, ou seja, 112.000 contratações a menos do que o relatado. bys/dw/dga/mel/dd",
    "highlightText": "",
    "highlightTitle": "",
    "highlightThreadTitle": "",
    "language": "portuguese",
    "sentiment": "negative",
    "categories": [
      "Economy, Business and Finance",
      "Social Issue",
      "Weather"
    ],
    "ai_allow": true,
    "canonical": false,
    "webz_reporter": false,
    "external_links": [],
    "external_images": [],
    "entities": {
      "persons": [],
      "organizations": [],
      "locations": []
    },
    "syndication": {
      "syndicated": null,
      "syndicate_id": null,
      "first_syndicated": false
    },
    "rating": null,
    "crawled": "2024-11-01T16:09:52.143+02:00",
    "updated": "2024-11-01T16:09:52.143+02:00"
  },
  {
    "uuid": "731e20a57ed0fb2f7d9b4d5286323fbcf60a7ed0",
    "url": "https://www.stocktitan.net/news/MESO/mesoblast-files-request-for-type-b-meeting-with-fda-to-discuss-org09svwpn8w.html",
    "ord_in_thread": 0,
    "author": "StockTitan",
    "published": "2025-04-02T23:15:00Z",
    "title": "Mesoblast Advances FDA Fast-Track Approval Plan for Heart Failure Drug | MESO Stock News",
    "text": "Mesoblast Files Request for Type B Meeting with FDA to Discuss Accelerated Approval Pathway for Revascor® in Ischemic Heart Failure\nMesoblast (MESO) has filed a request for a Type B meeting with the FDA to discuss the accelerated approval pathway for Revascor® in treating ischemic chronic heart failure with reduced ejection fraction (HFrEF) and inflammation. The meeting, expected this quarter, will be held under Mesoblast's Regenerative Medicines Advanced Therapy (RMAT) designation.\nIn a previous Type B meeting, the FDA indicated Mesoblast's eligibility to file for accelerated approval for Revascor in end-stage HFrEF patients, based on data from two randomized controlled trials. The FDA also specified the requirement for a single confirmatory trial in class II/III patients with ischemic HFrEF and inflammation post-approval.\nThe upcoming meeting aims to obtain FDA feedback on chemistry, manufacturing & controls (CMC), align on potency assays for commercial product release, and discuss the proposed design and primary endpoint for the confirmatory trial.\nMesoblast (MESO) ha presentato una richiesta per un incontro di Tipo B con la FDA per discutere il percorso di approvazione accelerata per Revascor® nel trattamento dell'insufficienza cardiaca ischemica cronica con frazione di eiezione ridotta (HFrEF) e infiammazione. L'incontro, previsto per questo trimestre, si terrà sotto la designazione di Regenerative Medicines Advanced Therapy (RMAT) di Mesoblast.\nIn un precedente incontro di Tipo B, la FDA ha indicato l'idoneità di Mesoblast a presentare una richiesta di approvazione accelerata per Revascor nei pazienti con HFrEF in fase terminale, basandosi su dati provenienti da due studi clinici controllati randomizzati. La FDA ha anche specificato il requisito di un singolo studio di conferma nei pazienti di classe II/III con HFrEF ischemica e infiammazione dopo l'approvazione.\nL'incontro imminente mira a ottenere un feedback dalla FDA su chimica, produzione e controlli (CMC), allinearsi sugli assay di potenza per il rilascio del prodotto commerciale e discutere il design proposto e l'obiettivo primario per lo studio di conferma.\nMesoblast (MESO) ha presentado una solicitud para una reunión de Tipo B con la FDA para discutir la vía de aprobación acelerada para Revascor® en el tratamiento de la insuficiencia cardíaca crónica isquémica con fracción de eyección reducida (HFrEF) y la inflamación. La reunión, que se espera para este trimestre, se llevará a cabo bajo la designación de Regenerative Medicines Advanced Therapy (RMAT) de Mesoblast.\nEn una reunión anterior de Tipo B, la FDA indicó la elegibilidad de Mesoblast para solicitar la aprobación acelerada de Revascor en pacientes con HFrEF en etapa terminal, basándose en datos de dos ensayos controlados aleatorios. La FDA también especificó el requisito de un único ensayo de confirmación en pacientes de clase II/III con HFrEF isquémica e inflamación después de la aprobación.\nLa próxima reunión tiene como objetivo obtener retroalimentación de la FDA sobre química, fabricación y controles (CMC), alinearse en los ensayos de potencia para el lanzamiento del producto comercial y discutir el diseño propuesto y el objetivo primario para el ensayo de confirmación.\nMesoblast (MESO)는 FDA와의 B형 회의 요청서를 제출하여 Revascor®의 승인 가속화 경로에 대해 논의하고 있습니다. 이 약물은 감소된 박출률을 가진 허혈성 만성 심부전(HFrEF) 및 염증 치료에 사용됩니다. 이번 회의는 이번 분기 중에 열릴 예정이며, Mesoblast의 Regenerative Medicines Advanced Therapy (RMAT) 지명 아래 진행됩니다.\n이전 B형 회의에서 FDA는 HFrEF 말기 환자에 대한 Revascor의 승인 가속화 요청 자격을 확인했으며, 이는 두 개의 무작위 대조 시험의 데이터를 기반으로 합니다. 또한 FDA는 승인 후 허혈성 HFrEF 및 염증이 있는 II/III 등급 환자를 대상으로 한 단일 확인 시험의 필요성을 명시했습니다.\n다가오는 회의는 화학, 제조 및 품질 관리(CMC)에 대한 FDA의 피드백을 얻고, 상업적 제품 출시를 위한 효능 시험에 대해 조율하며, 확인 시험의 제안된 설계 및 주요 목표에 대해 논의하는 것을 목표로 합니다.\nMesoblast (MESO) a déposé une demande de réunion de Type B auprès de la FDA pour discuter du chemin d'approbation accélérée pour Revascor® dans le traitement de l'insuffisance cardiaque chronique ischémique avec fraction d'éjection réduite (HFrEF) et inflammation. La réunion, prévue pour ce trimestre, se tiendra sous la désignation de Regenerative Medicines Advanced Therapy (RMAT) de Mesoblast.\nLors d'une précédente réunion de Type B, la FDA a indiqué l'éligibilité de Mesoblast à demander une approbation accélérée pour Revascor chez les patients en phase terminale de HFrEF, sur la base des données de deux essais contrôlés randomisés. La FDA a également précisé l'exigence d'un essai de confirmation unique chez les patients de classe II/III avec HFrEF ischémique et inflammation après approbation.\nLa prochaine réunion vise à obtenir des retours de la FDA sur la chimie, la fabrication et les contrôles (CMC), à s'aligner sur les essais de puissance pour le lancement du produit commercial et à discuter du design proposé et de l'objectif principal pour l'essai de confirmation.\nMesoblast (MESO) hat einen Antrag auf ein Typ-B-Meeting bei der FDA eingereicht, um den beschleunigten Genehmigungsweg für Revascor® zur Behandlung von ischämischer chronischer Herzinsuffizienz mit reduzierter Ejektionsfraktion (HFrEF) und Entzündung zu besprechen. Das Treffen, das in diesem Quartal erwartet wird, wird unter der Regenerative Medicines Advanced Therapy (RMAT)-Bezeichnung von Mesoblast stattfinden.\nIn einem früheren Typ-B-Meeting hat die FDA die Berechtigung von Mesoblast zur Beantragung einer beschleunigten Genehmigung für Revascor bei Patienten mit fortgeschrittener HFrEF bestätigt, basierend auf Daten aus zwei randomisierten kontrollierten Studien. Die FDA hat auch die Anforderung an eine einzige Bestätigungsstudie bei Patienten der Klassen II/III mit ischämischer HFrEF und Entzündung nach der Genehmigung spezifiziert.\nDas bevorstehende Meeting zielt darauf ab, Feedback von der FDA zu Chemie, Herstellung und Kontrollen (CMC) zu erhalten, sich auf Potenzassays für die kommerzielle Produktfreigabe abzustimmen und das vorgeschlagene Design sowie den primären Endpunkt für die Bestätigungsstudie zu besprechen.\n- FDA previously confirmed eligibility for accelerated approval pathway\n- RMAT designation status maintained for Revascor\n- Only one confirmatory trial required post-approval\n- Additional clinical trial required post-approval\n- Still pending FDA feedback on manufacturing and potency assays\n- Final approval timeline remains uncertain\nNEW YORK, April 02, 2025 (GLOBE NEWSWIRE) -- Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on its plans to meet with the United States Food and Drug Administration (FDA) to discuss the accelerated approval pathway for Revascor® (rexlemestrocel-L) in the treatment of patients with ischemic chronic heart failure with reduced ejection fraction (HFrEF) and inflammation.\nMesoblast filed a request for a Type B meeting during the last quarter, in line with previous guidance, and expects to have the meeting during this quarter. The meeting will be held under Mesoblast’s Regenerative Medicines Advanced Therapy (RMAT) designation for REVASCOR.\nIn a Type B meeting last year, FDA provided guidance to Mesoblast that the company was eligible to file for accelerated approval of REVASCOR in patients with end-stage HFrEF based on the totality of data across two randomized controlled trials. FDA also guided that a single confirmatory trial in class II/III patients with ischemic HFrEF and inflammation will need to be completed after any accelerated approval is obtained.\nThe key objectives of the meeting are to obtain FDA feedback on relevant chemistry, manufacturing & controls (CMC), alignment on potency assays for commercial product release, and Mesoblast’s proposed design and primary endpoint for the confirmatory trial.\nAbout Mesoblast\nMesoblast (the Company) is a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The therapies from the Company’s proprietary mesenchymal lineage cell therapy technology platform respond to severe inflammation by releasing anti-inflammatory factors that counter and modulate multiple effector arms of the immune system, resulting in significant reduction of the damaging inflammatory process.\nMesoblast’s RYONCIL® (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients 2 months and older is the first FDA approved mesenchymal stromal cell (MSC) therapy. Please see the full Prescribing Information at www.ryoncil.com.\nMesoblast is committed to developing additional cell therapies for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. RYONCIL is being developed for additional inflammatory diseases including SR-aGvHD in adults and biologic-resistant inflammatory bowel disease. Rexlemestrocel-L is being developed for heart failure and chronic low back pain. The Company has established commercial partnerships in Japan, Europe and China.\nAbout Mesoblast intellectual property: Mesoblast has a strong and extensive global intellectual property portfolio, with over 1,000 granted patents or patent applications covering mesenchymal stromal cell compositions of matter, methods of manufacturing and indications. These granted patents and patent applications are expected to provide commercial protection extending through to at least 2041 in major markets.\nAbout Mesoblast manufacturing: The Company’s proprietary manufacturing processes yield industrial-scale, cryopreserved, off-the-shelf, cellular medicines. These cell therapies, with defined pharmaceutical release criteria, are planned to be readily available to patients worldwide.\nMesoblast has locations in Australia, the United States and Singapore and is listed on the Australian Securities Exchange (MSB) and on the Nasdaq (MESO). For more information, please see www.mesoblast.com, LinkedIn: Mesoblast Limited and X: @Mesoblast\nForward-Looking Statements\nThis press release includes forward-looking statements that relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Forward-looking statements should not be read as a guarantee of future performance or results, and actual results may differ from the results anticipated in these forward-looking statements, and the differences may be material and adverse. Forward-looking statements include, but are not limited to, statements about: the initiation, timing, progress and results of Mesoblast’s preclinical and clinical studies, and Mesoblast’s research and development programs; Mesoblast’s ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; Mesoblast’s ability to advance its manufacturing capabilities; the timing or likelihood of regulatory filings and approvals, manufacturing activities and product marketing activities, if any; the commercialization of Mesoblast’s RYONCIL for pediatric SR-aGvHD and any other product candidates, if approved; regulatory or public perceptions and market acceptance surrounding the use of stem-cell based therapies; the potential for Mesoblast’s product candidates, if any are approved, to be withdrawn from the market due to patient adverse events or deaths; the potential benefits of strategic collaboration agreements and Mesoblast’s ability to enter into and maintain established strategic collaborations; Mesoblast’s ability to establish and maintain intellectual property on its product candidates and Mesoblast’s ability to successfully defend these in cases of alleged infringement; the scope of protection Mesoblast is able to establish and maintain for intellectual property rights covering its product candidates and technology; estimates of Mesoblast’s expenses, future revenues, capital requirements and its needs for additional financing; Mesoblast’s financial performance; developments relating to Mesoblast’s competitors and industry; and the pricing and reimbursement of Mesoblast’s product candidates, if approved. You should read this press release together with our risk factors, in our most recently filed reports with the SEC or on our website. Uncertainties and risks that may cause Mesoblast’s actual results, performance or achievements to be materially different from those which may be expressed or implied by such statements, and accordingly, you should not place undue reliance on these forward-looking statements. We do not undertake any obligations to publicly update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise.\nRelease authorized by the Chief Executive.\nFor more information, please contact:\nCorporate Communications / Investors | |\nPaul Hughes | |\nT: +61 3 9639 6036 | |\nMedia – Global | |\nAllison Worldwide | |\nEmma Neal | |\nT: +1 603 545 4843 | |\nE:\n|",
    "highlightText": "",
    "highlightTitle": "",
    "highlightThreadTitle": "",
    "language": "english",
    "sentiment": "positive",
    "categories": [
      "Health",
      "Science and Technology",
      "Economy, Business and Finance"
    ],
    "topics": [
      "Health->health treatment and procedure",
      "Health->heart disease",
      "Health->drug rehabilitation",
      "Science and Technology->medical research",
      "Science and Technology->biomedical science",
      "Science and Technology->scientific research",
      "Economy, Business and Finance->financial and economic news",
      "Economy, Business and Finance->business financing",
      "Economy, Business and Finance->healthcare industry"
    ],
    "ai_allow": true,
    "has_canonical": false,
    "breaking": true,
    "webz_reporter": false,
    "external_links": [
      "https://www.globenewswire.com/Tracker?data=PqPOvd1-EdVdPnXYio9PgPJ4fG1d06aQKQBGDW0O2aF7FUYaXXRPOhQAMOKETOdJ7VGHg8_hJiLVUVReK4IeYWqBoYlUGV7s6IlTMHFBXrlO7J67Bjc-S3lkz62kBYjhuQBZqf21BosY36jmi3nYAK-M9VXAnAiK42W8D2CKnkM=",
      "https://www.globenewswire.com/Tracker?data=PPms1DnOAN_RnwAUfdoW4xONsCoFTUKI7F85v-PRcpfYDR5BrN2RjVw8QHWHbjaXHR94Y7jd8DDZtJqwRFOeobzm_AkgndfJB2gmCQqQQSo=",
      "https://www.globenewswire.com/Tracker?data=a296ayhFHajSg1R8ZoQrM-27XIdHxcBQASu6Mvzt7AmUL1mkA6vXLuFLgad3AnUHjyJ1CG9Bhnhc6X09QT2jig==",
      "https://www.globenewswire.com/Tracker",
      "https://globenewswire.com/Tracker?data=a296ayhFHajSg1R8ZoQrM-27XIdHxcBQASu6Mvzt7AmUL1mkA6vXLuFLgad3AnUHjyJ1CG9Bhnhc6X09QT2jig==",
      "https://globenewswire.com/Tracker?data=PqPOvd1-EdVdPnXYio9PgPJ4fG1d06aQKQBGDW0O2aF7FUYaXXRPOhQAMOKETOdJ7VGHg8_hJiLVUVReK4IeYWqBoYlUGV7s6IlTMHFBXrlO7J67Bjc-S3lkz62kBYjhuQBZqf21BosY36jmi3nYAK-M9VXAnAiK42W8D2CKnkM=",
      "https://globenewswire.com/Tracker?data=PPms1DnOAN_RnwAUfdoW4xONsCoFTUKI7F85v-PRcpfYDR5BrN2RjVw8QHWHbjaXHR94Y7jd8DDZtJqwRFOeobzm_AkgndfJB2gmCQqQQSo="
    ],
    "entities": {
      "persons": [
        {
          "name": "questo trimestre",
          "sentiment": "positive"
        },
        {
          "name": "La FDA",
          "sentiment": "positive"
        },
        {
          "name": "La",
          "sentiment": "positive"
        },
        {
          "name": "que se espera para este trimestre",
          "sentiment": "positive"
        },
        {
          "name": "se llevará",
          "sentiment": "positive"
        },
        {
          "name": "prévue pour ce trimestre",
          "sentiment": "positive"
        },
        {
          "name": "tiendra sous",
          "sentiment": "positive"
        },
        {
          "name": "Das Treffen",
          "sentiment": "positive"
        },
        {
          "name": "wird unter",
          "sentiment": "positive"
        },
        {
          "name": "Bestätigungsstudie",
          "sentiment": "positive"
        },
        {
          "name": "Endpunkt",
          "sentiment": "positive"
        },
        {
          "name": "basandosi su dati provenienti da due studi clinici controllati randomizzati",
          "sentiment": "negative"
        },
        {
          "name": "accélérée pour",
          "sentiment": "negative"
        },
        {
          "name": "contrôlés randomisés",
          "sentiment": "negative"
        },
        {
          "name": "di conferma",
          "sentiment": "neutral"
        },
        {
          "name": "presentado una solicitud para una reunión de Tipo",
          "sentiment": "neutral"
        },
        {
          "name": "para discutir la vía de",
          "sentiment": "neutral"
        },
        {
          "name": "Revascor의",
          "sentiment": "neutral"
        },
        {
          "name": "기반으로 합니다",
          "sentiment": "neutral"
        },
        {
          "name": "einen Antrag auf ein Typ-B-Meeting",
          "sentiment": "neutral"
        },
        {
          "name": "früheren Typ-B-Meeting",
          "sentiment": "neutral"
        },
        {
          "name": "Berechtigung von Mesoblast zur Beantragung",
          "sentiment": "neutral"
        },
        {
          "name": "fortgeschrittener",
          "sentiment": "neutral"
        },
        {
          "name": "randomisierten kontrollierten Studien",
          "sentiment": "neutral"
        },
        {
          "name": "Anforderung",
          "sentiment": "neutral"
        },
        {
          "name": "Klassen II/",
          "sentiment": "neutral"
        },
        {
          "name": "Entzündung",
          "sentiment": "neutral"
        },
        {
          "name": "Genehmigung",
          "sentiment": "neutral"
        },
        {
          "name": "darauf ab",
          "sentiment": "neutral"
        },
        {
          "name": "Herstellung",
          "sentiment": "neutral"
        },
        {
          "name": "sich auf Potenzassays",
          "sentiment": "neutral"
        },
        {
          "name": "LinkedIn",
          "sentiment": "neutral"
        },
        {
          "name": "Emma Neal",
          "sentiment": "neutral"
        }
      ],
      "locations": [
        {
          "name": "La réunion",
          "sentiment": "positive"
        },
        {
          "name": "diesem Quartal erwartet wird",
          "sentiment": "positive"
        },
        {
          "name": "sur la",
          "sentiment": "negative"
        },
        {
          "name": "il",
          "sentiment": "neutral"
        },
        {
          "name": "NEW YORK",
          "sentiment": "neutral"
        },
        {
          "name": "Japan",
          "sentiment": "neutral"
        },
        {
          "name": "Europe",
          "sentiment": "neutral"
        },
        {
          "name": "China",
          "sentiment": "neutral"
        },
        {
          "name": "Australia",
          "sentiment": "neutral"
        },
        {
          "name": "the United States",
          "sentiment": "neutral"
        },
        {
          "name": "Singapore",
          "sentiment": "neutral"
        }
      ],
      "organizations": [
        {
          "name": "di Regenerative Medicines Advanced Therapy",
          "sentiment": "positive",
          "tickers": []
        },
        {
          "name": "cabo bajo la designación",
          "sentiment": "positive",
          "tickers": []
        },
        {
          "name": "de Regenerative Medicines Advanced Therapy (RMAT) de Mesoblast",
          "sentiment": "positive",
          "tickers": []
        },
        {
          "name": "Mesoblast의 Regenerative Medicines Advanced",
          "sentiment": "positive",
          "tickers": []
        },
        {
          "name": "l'exigence d'un essai de",
          "sentiment": "positive",
          "tickers": []
        },
        {
          "name": "chez les",
          "sentiment": "positive",
          "tickers": []
        },
        {
          "name": "un precedente incontro di Tipo B",
          "sentiment": "negative",
          "tickers": []
        },
        {
          "name": "di Mesoblast",
          "sentiment": "negative",
          "tickers": []
        },
        {
          "name": "presentare una richiesta di approvazione accelerata per",
          "sentiment": "negative",
          "tickers": []
        },
        {
          "name": "Lors d'une précédente réunion de Type B",
          "sentiment": "negative",
          "tickers": []
        },
        {
          "name": "ASX",
          "sentiment": "negative",
          "tickers": []
        },
        {
          "name": "the United States Food and Drug Administration",
          "sentiment": "negative",
          "tickers": []
        },
        {
          "name": "Rexlemestrocel-L",
          "sentiment": "negative",
          "tickers": []
        },
        {
          "name": "manufacturing & controls",
          "sentiment": "neutral",
          "tickers": []
        },
        {
          "name": "CMC",
          "sentiment": "neutral",
          "tickers": []
        },
        {
          "name": "presentato una richiesta",
          "sentiment": "neutral",
          "tickers": []
        },
        {
          "name": "un incontro di Tipo",
          "sentiment": "neutral",
          "tickers": []
        },
        {
          "name": "il percorso di approvazione accelerata per",
          "sentiment": "neutral",
          "tickers": []
        },
        {
          "name": "anche specificato il requisito di un singolo",
          "sentiment": "neutral",
          "tickers": []
        },
        {
          "name": "di conferma nei pazienti di classe II/III",
          "sentiment": "neutral",
          "tickers": []
        },
        {
          "name": "un feedback dalla FDA su chimica",
          "sentiment": "neutral",
          "tickers": []
        },
        {
          "name": "di potenza",
          "sentiment": "neutral",
          "tickers": []
        },
        {
          "name": "en el tratamiento de la",
          "sentiment": "neutral",
          "tickers": []
        },
        {
          "name": "con fracción de eyección",
          "sentiment": "neutral",
          "tickers": []
        },
        {
          "name": "de Tipo B",
          "sentiment": "neutral",
          "tickers": []
        },
        {
          "name": "la elegibilidad de Mesoblast para solicitar la",
          "sentiment": "neutral",
          "tickers": []
        },
        {
          "name": "en datos de dos ensayos controlados",
          "sentiment": "neutral",
          "tickers": []
        },
        {
          "name": "el requisito de un único ensayo de confirmación en pacientes de clase II/III con HFrEF",
          "sentiment": "neutral",
          "tickers": []
        },
        {
          "name": "La próxima reunión tiene como objetivo obtener retroalimentación de la FDA sobre química",
          "sentiment": "neutral",
          "tickers": []
        },
        {
          "name": "fabricación y",
          "sentiment": "neutral",
          "tickers": []
        },
        {
          "name": "alinearse en los ensayos de potencia para el lanzamiento del producto comercial y discutir",
          "sentiment": "neutral",
          "tickers": []
        },
        {
          "name": "el diseño propuesto y el objetivo primario para el ensayo de",
          "sentiment": "neutral",
          "tickers": []
        },
        {
          "name": "B형",
          "sentiment": "neutral",
          "tickers": []
        },
        {
          "name": "une demande de réunion de Type B auprès de la FDA",
          "sentiment": "neutral",
          "tickers": []
        },
        {
          "name": "dans le traitement de l'insuffisance cardiaque chronique ischémique avec fraction d'éjection",
          "sentiment": "neutral",
          "tickers": []
        },
        {
          "name": "La prochaine réunion vise à obtenir des retours de la FDA sur la chimie",
          "sentiment": "neutral",
          "tickers": []
        },
        {
          "name": "Daten aus zwei",
          "sentiment": "neutral",
          "tickers": []
        },
        {
          "name": "GLOBE NEWSWIRE",
          "sentiment": "neutral",
          "tickers": []
        },
        {
          "name": "MSB",
          "sentiment": "neutral",
          "tickers": []
        },
        {
          "name": "Company",
          "sentiment": "neutral",
          "tickers": []
        },
        {
          "name": "RYONCIL",
          "sentiment": "neutral",
          "tickers": []
        },
        {
          "name": "SR-aGvHD",
          "sentiment": "neutral",
          "tickers": []
        },
        {
          "name": "MSC",
          "sentiment": "neutral",
          "tickers": []
        },
        {
          "name": "SR",
          "sentiment": "neutral",
          "tickers": [
            {
              "ticker": "SR",
              "exchange": "NYSE"
            }
          ]
        },
        {
          "name": "the Australian Securities Exchange",
          "sentiment": "neutral",
          "tickers": []
        },
        {
          "name": "Mesoblast Limited",
          "sentiment": "neutral",
          "tickers": []
        },
        {
          "name": "the Private Securities Litigation Reform Act",
          "sentiment": "neutral",
          "tickers": []
        },
        {
          "name": "Paul Hughes",
          "sentiment": "neutral",
          "tickers": []
        },
        {
          "name": "Allison Worldwide",
          "sentiment": "neutral",
          "tickers": []
        }
      ]
    },
    "syndication": {
      "syndicated": false,
      "syndicate_id": null,
      "first_syndicated": false
    },
    "trust": {
      "categories": [],
      "bias": null
    },
    "rating": null,
    "crawled": "2025-04-03T02:33:52.060+03:00",
    "updated": "2025-04-03T02:33:52.060+03:00"
  },
  {
    "uuid": "2624796e8bd40408178744d6cb29771f77d90e26",
    "url": "https://www.dailybreeze.com/2024/11/29/which-us-industries-bet-big-on-noncitizen-workers",
    "ord_in_thread": 0,
    "parent_url": null,
    "author": "Jonathan Lansner",
    "published": "2024-11-29T13:03:00Z",
    "title": "Which US industries bet big on noncitizen workers? – Daily Breeze",
    "text": "If tougher immigration policies mean a significant loss of workers, American business hardships will lean toward industries with lower-wage jobs.\nPresident-elect Donald Trump has strongly hinted that he’ll order significant deportations of people living in the US without proper documentation. Others can debate the societal, constitutional and political ramifications of such a forced exodus, but my trusty spreadsheet is just looking at how many workers the nation’s economy could lose. One challenge of debating the business value of immigrants – especially those without proper paperwork – is that statistics on the legal status of immigrant workers are hard to find. Consider the Census Bureau’s statistics on worker citizenship. It tracks “noncitizens” – a broad category that includes workers from other countries who are approved to be employed in the US, plus those who don’t have such authorization. Please remember this significant caveat as my spreadsheet looks at the census tally of employment sliced ​​by citizenship for 2022, the latest data available. By census math, there were 14.7 million “noncitizen” workers across the nation in 2022. That flock equaled 9% of all people employed in 2022. And as one comparison, the US averaged 6 million officially unemployed workers that year. So what kind of work do noncitizens do? Census stats track employment by citizenship within 16 industries. The data doesn’t track wages but other figures tell us incomes for all workers in these industries. That gives us hints about what size paychecks noncitizens earn. Start with this number: The typical American worker made $48,100-a-year median in 2023. Next, consider that of those 16 industries tracked, nine produce annual incomes wages below the US norm, collectively running $35,000. These low-wage industries employed 8.8 million noncitizens workers. That group equals 13% of total employment in these industries. It’s a sharp contrast to the seven industries with wages above the norm, where the typical worker earns $66,500. These businesses had 5.9 million noncitizens on the job – just 7% of all their staffing. So what US industries made the biggest bets on noncitizen workers?Trades commonly with gritty workdays, often for meek pay. Think about these job clusters, ranked by the noncitizen worker’s share of all jobs … Farming-fishing-forestry: 320,000 noncitizen workers – 33% of all jobs in the industry. The industry-wide median income was $28,800. Building and grounds cleaning, maintenance: 1.5 million workers are noncitizens – that’s 28% of all jobs in an industry with typical annual incomes of $27,300. Construction and extraction: 2.1 million noncitizens – 26% of all jobs with incomes of $46,200. Food prep/serving: 1.3 million noncitizens – 16% of all jobs with incomes of $19,600. Production-manufacturing: 1.1 million noncitizens – 14% of all jobs. Incomes of $42,000. Computer-engineering-science: 1.4 million noncitizens – 13% of all jobs with incomes of $91,500. Transportation, materials moving: 1.4 million noncitizens – 12% of all jobs. Incomes of $38,100. Healthcare support: 456,000 noncitizens – 9% of all jobs with incomes of $30,300. Installation, maintenance, and repair: 462,000 noncitizens – 9% of all jobs with incomes of $52,100. Personal care and service: 354,000 noncitizens – 9% of all jobs. Incomes of $22,100. Sales and related: 817,000 noncitizens – 6% of all jobs with incomes of $39,200. Office and administrative support: 850,000 noncitizens – 5% of all jobs with incomes of $39,600. Management, business, and financial: 1.5 million noncitizens – 5% of all jobs with incomes of $80,900. Education, legal, community service, arts, and media: 725,000 noncitizens – 4% of all jobs with incomes of $51,200. Protective service: 103,000 noncitizens – 3% of all jobs with incomes of $54,300. Healthcare practitioners and technicians: 323,000 noncitizens – 3% of all jobs with incomes of $70,900.Supporters of immigrant workers are an interesting coalition that includes numerous corporate types.Let’s be honest. People without paperwork seem to find someone to hire them.The business logic supporting noncitizen workers is rather simple. They often do jobs many Americans wouldn’t consider – and frequently do them cheaply.Critics of these hiring habits say noncitizens – with or without authorization – often steal jobs from American citizens. Plus, their mere presence in the workforce lowers wages for competing US workers.But who knows if there are enough citizens willing to do such work if job opportunities were created?At a minimum, any large-scale deportations – or not-so-subtle nudges to exit – could be extremely disruptive to the industries heavy with workers lacking paperwork.Assuming a significant loss of noncitizen workers, it’s a reasonable guess that US employers will raise wages to fill the newly vacant positions. Yes, that could put extra cash in citizens’ wallets. However, it’s also a decent assumption that these same bosses will pass along their higher labor expenses with increased prices of their products. That might muddle the nation’s struggles with stubbornly high inflation. Jonathan Lansner is the business columnist for the Southern California News Group. He can be reached at jlansner@scng.com",
    "highlightText": "",
    "highlightTitle": "",
    "highlightThreadTitle": "",
    "language": "english",
    "sentiment": "negative",
    "categories": [
      "Economy, Business and Finance",
      "Social Issue",
      "Labor"
    ],
    "ai_allow": true,
    "canonical": false,
    "webz_reporter": false,
    "external_links": [],
    "external_images": [],
    "entities": {
      "persons": [
        {
          "name": "Donald Trump",
          "sentiment": "none"
        }
      ],
      "organizations": [
        {
          "name": "Census Bureau",
          "sentiment": "none"
        }
      ],
      "locations": []
    },
    "syndication": {
      "syndicated": false,
      "syndicate_id": "2624796e8bd40408178744d6cb29771f77d90e26",
      "first_syndicated": true
    },
    "rating": null,
    "crawled": "2024-11-29T16:29:01.806+02:00",
    "updated": "2024-11-29T16:29:01.806+02:00"
  },
  {
    "uuid": "4298f13286139b219210f5bd9fe6b529cf398ed9",
    "url": "https://www.caughtoffside.com/2024/07/25/six-time-french-champions-forfeit-professional-status-contracts-of-all-players-terminated-and-training-ground-closed-in-sad-development",
    "ord_in_thread": 0,
    "parent_url": null,
    "author": "Mehdi Gokal",
    "published": "2024-07-25T00:00:00Z",
    "title": "Six-time French champions forfeit professional status: contracts of all players terminated and training ground closed in sad development | CaughtOffside",
    "text": "In a surprising and somber development, French side Bordeaux have announced they will no longer retain their professional status.\nThis decision comes after the club accepted relegation to the third tier of French football, primarily due to severe financial issues.\nBordeaux terminates player contracts and closes training centre According to a report from French outlet L’Equipe , Bordeaux will not renew its professional license.\nThis transition to a semi-professional model will result in the termination of all player contracts and the closure of the club’s training centre.\nAs reported by Sud Ouest , Bordeaux officially notified the French Football Federation (FFF) of their decision on Thursday.\nAlthough they finished 12th in Ligue 2 for the 2023/24 season, Bordeaux’s financial troubles led to their administrative relegation to the Championnat National, a semi-professional league.\nLiverpool owners Fenway Sports Group (FSG) were previously in discussions about a potential takeover but eventually pulled out.\nHad they proceeded with the takeover, it could have prevented Bordeaux’s relegation. The withdrawal of FSG’s interest was a significant blow to the club’s hopes of financial recovery and maintaining their professional status.\nMore Stories / Latest News\nGreat news for Man United fans as major €70m deal to be sealed next week Jul 25 2024, 22:38\nSix-time French champions forfeit professional status: contracts of all players terminated and training ground closed in sad development Jul 25 2024, 22:20\nArne Slot confirms three major players will join Liverpool’s pre-season tour in latest update on returning stars Jul 25 2024, 22:01 A sad day for a historic French club Bordeaux, one of France’s most prestigious clubs, boasts a remarkable history. They have won six Ligue 1 titles , with the most recent in 2008-09, and four Coupe de France titles, the last in 2012-13.\nThe club has been a breeding ground for French stars, including Barcelona’s Jules Kounde and Real Madrid’s Aurelien Tchouameni.\nThis marks a sad day for French football, as Bordeaux’s exit from the professional ranks signals the end of an era for a club with a storied legacy.\nThe decision to drop to a semi-professional status not only affects the club’s current players and staff but also leaves a void in French football history.",
    "highlightText": "",
    "highlightTitle": "",
    "highlightThreadTitle": "",
    "language": "english",
    "sentiment": "negative",
    "categories": [
      "Human Interest",
      "Sport"
    ],
    "webz_reporter": false,
    "external_links": [
      "https://www.lequipe.fr/Football/Actualites/Bordeaux-abandonne-son-statut-professionnel-apres-sa-retrogradation-en-national/1485185",
      "https://www.sudouest.fr/sport/football/girondins-de-bordeaux/girondins-de-bordeaux-le-club-va-abandonner-son-statut-professionnel-les-joueurs-seront-liberes-et-le-centre-de-formation-ferme-20685009.php?csnt=190eaa3245b",
      "https://www.transfermarkt.com/fc-girondins-bordeaux/pokalhistorie/verein/40",
      "https://www.sudouest.fr/sport/football/girondins-de-bordeaux/girondins-de-bordeaux-le-club-va-abandonner-son-statut-professionnel-les-joueurs-seront-liberes-et-le-centre-de-formation-ferme-20685009.php",
      "https://transfermarkt.com/fc-girondins-bordeaux/pokalhistorie/verein/40",
      "https://sudouest.fr/sport/football/girondins-de-bordeaux/girondins-de-bordeaux-le-club-va-abandonner-son-statut-professionnel-les-joueurs-seront-liberes-et-le-centre-de-formation-ferme-20685009.php?csnt=190eaa3245b",
      "https://lequipe.fr/Football/Actualites/Bordeaux-abandonne-son-statut-professionnel-apres-sa-retrogradation-en-national/1485185"
    ],
    "external_images": [],
    "entities": {
      "persons": [
        {
          "name": "sud ouest",
          "sentiment": "none"
        }
      ],
      "organizations": [
        {
          "name": "championnat national",
          "sentiment": "none"
        },
        {
          "name": "fenway sports group",
          "sentiment": "none"
        },
        {
          "name": "liverpool",
          "sentiment": "none"
        },
        {
          "name": "french football federation",
          "sentiment": "none"
        },
        {
          "name": "ligue",
          "sentiment": "none"
        }
      ],
      "locations": [
        {
          "name": "bordeaux",
          "sentiment": "none"
        }
      ]
    },
    "rating": null,
    "crawled": "2024-07-26T01:12:35.645+03:00",
    "updated": "2024-07-26T05:22:21.559+03:00"
  },
  {
    "uuid": "0f13d7ab7778793041849d00899fb528ba034962",
    "url": "https://www.franceguyane.fr/actualite/politique/elections-de-la-collectivite-territoriale-de-guyane/route-du-fleuve-la-ctg-vote-a-lunanimite-le-projet-de-desenclavement-1031965.php",
    "ord_in_thread": 0,
    "author": "J.LP",
    "published": "2025-04-16T21:23:00Z",
    "title": "Route du fleuve : la CTG vote à l'unanimité le projet de désenclavement",
    "text": "Route du fleuve : la CTG vote à l'unanimité le projet de désenclavement\nLes élus de la Collectivité Territoriale de la Guyane (CTG) ont voté à l'unanimité le lancement d'études préalables à la construction de la route du fleuve, ce mercredi 16 avril, lors d'une assemblée plénière.\nDans la salle de délibérations de la CTG, toutes les mains se sont levées en faveur de cette étape cruciale vers le désenclavement des communes du Haut-Maroni. L'ensemble des élus a approuvé le lancement des études techniques nécessaires à la réalisation de cette route tant attendue.\nParmi les points de convergence : l'article 5 de la délibération, “rejette la proposition d'une piste \"et qui “affirme la nécessité de construire une route revêtue”.\nRejet d'une piste, exigence d'une route\nUne...",
    "highlightText": "",
    "highlightTitle": "",
    "highlightThreadTitle": "",
    "language": "french",
    "sentiment": "positive",
    "categories": [
      "Politics",
      "Economy, Business and Finance",
      "Social Issue"
    ],
    "topics": [
      "Politics->local government and authority",
      "Politics->government policy",
      "Economy, Business and Finance->construction and property",
      "Economy, Business and Finance->business governance",
      "Social Issue->social services",
      "Social Issue->demographics",
      "Social Issue->communities"
    ],
    "ai_allow": true,
    "has_canonical": false,
    "breaking": false,
    "webz_reporter": false,
    "external_links": [],
    "entities": {
      "persons": [],
      "locations": [],
      "organizations": []
    },
    "syndication": {
      "syndicated": null,
      "syndicate_id": null,
      "first_syndicated": false
    },
    "trust": {
      "categories": [],
      "bias": null,
      "source": {
        "type": null,
        "city": null,
        "state": null,
        "country": null,
        "domain_type": null,
        "agency": null,
        "organization_name": null
      }
    },
    "rating": null,
    "crawled": "2025-04-17T00:37:36.432+03:00",
    "updated": "2025-04-17T00:37:36.432+03:00"
  },
  {
    "uuid": "62f4c1ca602dea3b3f02a00d50c8068e83d9c530",
    "url": "https://www.ok.co.uk/celebrity-news/mafs-shona-manderson-reveals-acne-31764658",
    "ord_in_thread": 0,
    "parent_url": null,
    "author": "web.help@express.co.uk (Lucretia Munro, Amy Jones)",
    "published": "2023-12-28T21:55:00Z",
    "title": "MAFS' Shona Manderson reveals acne battle as she displays 'real skin'",
    "text": "Married At First Sight star Shona Manderson has bravely revealed her secret battle with acne.\nThe 31 year old reality\nTV star took to Instagram to share a make-up free selfie and an \"acne update\" with her 143K followers. In the candid post, she said: \"Acne update. My skin was great after my peel I was buzzing with it but it's flared up again.\n\"I decided to finally go to the GP and I've been given 3 months of Lymecycline (antibiotics) and acnecide gel. For those interested I'll keep you updated with how I get on and if anyone's taken before please let me know how you got on I was really reluctant to take antibiotics but they're like cysts and so red!\"\nIn the skin update, she continued to say: \"Thank you so much for your kind messages about my skin. I'm taking so many tips and I really appreciate you reaching out.\"\nWhile acne is a common skin condition, Shona attributed her skin battle to her contraception - an IUD. This produces a progesterone hormone, which is an androgen.\nTalking about this she said: \"Here's a little update where I'm at, so my spots seem to be like here, here, here, got them really bad on my chin. But I'm getting my coil removed on Monday so hopefully... fingers crossed.\"\nShona became a fan favourite on MAFS, after going through a controlling relationship with Brad Kelly during her time on the show. Viewers were thrilled when she returned for the last dinner party of the series, appearing to be back to her old confident self, leaving Brad behind.\nAfter her split from Brad, Shona fell for another man from the show, Matt Pilmoor, who had originally been married to Adrienne Naylor. The couple\nexclusively revealed their new relationship to OK! and said they want to get married and have children.\nMatt said: \"We definitely want to get married. Getting married abroad would be lovely but logically we would do it in the UK for family coming. We do need money so there will be no ring anytime soon! But I would love to propose at some point. Let's see how the next year goes in terms of finances but it's definitely on the cards!\"\nWhile Shona shared: \"Yeah we've spoken about getting married. Matt has said he will wear a kilt because my family are Scottish. We've spoken about engagement rings, we just need the money first.\"\nAnd when it comes to creating a family, it appears they are both on the same page. \"I want two kids. I'm 32 next year so I definitely want babies in the next few years. It's mental but when you know, you know, and it just works. And it can move at a healthy pace. I don't even feel scared about anything\", Shona revealed.\nAfter confirming their relationship last month, the 32 year old opened up further and said: \"We have a really healthy, happy, safe, fun, relationship - I really appreciate Matt, it's what I deserve, we deserve each other.\"\nThe couple admitted to having to keep their relationship under wraps until MAFS had finished being aired.\nExplaining this Shona said: \"Matt would be driving and I would be in the back, we would be walking around Nottingham and I'd be all the way over there, we were like secret agents on a mission.\" Adding: \"I'm proud to be his girlfriend and it just works.\"\n* This article was crafted with the help of an AI engine, which speeds up OK!'s editorial research and applies it to article templates created by journalists in our newsrooms. An OK! editor reviewed this content before it was published. You can report any errors to",
    "highlightText": "",
    "highlightTitle": "",
    "highlightThreadTitle": "",
    "language": "english",
    "sentiment": "positive",
    "categories": [
      "Human Interest",
      "Health",
      "Arts, Culture and Entertainment"
    ],
    "external_links": [],
    "external_images": [],
    "entities": {
      "persons": [
        {
          "name": "shona manderson",
          "sentiment": "positive"
        },
        {
          "name": "shona",
          "sentiment": "none"
        }
      ],
      "organizations": [
        {
          "name": "first sight",
          "sentiment": "positive"
        },
        {
          "name": "instagram",
          "sentiment": "none"
        }
      ],
      "locations": []
    },
    "rating": null,
    "crawled": "2023-12-29T00:10:35.402+02:00",
    "updated": "2023-12-29T00:10:35.402+02:00"
  }
]